NCT06224413View on ClinicalTrials.gov

A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel

RecruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

March 27, 2024

Primary Completion Date

December 30, 2047

Study Completion Date

December 30, 2047

Conditions
Cerebral Adrenoleukodystrophy (CALD)
Interventions
OTHER

No Intervention

This is non-interventional study.

Trial Locations (3)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

75390

RECRUITING

UT Southwestern Medical Center, Dallas

02115

RECRUITING

Boston Children's Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Center for International Blood and Marrow Transplant Research

NETWORK

lead

Genetix Biotherapeutics Inc.

INDUSTRY

NCT06224413 - A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel | Biotech Hunter | Biotech Hunter